For ophthalmic use only. Instill one drop in the conjunctival sac of the affected eye(s) once daily in the evening. If using other ophthalmic medications, wait at least 5 minutes between applications.

Travoprost is a highly selective prostaglandin F2α receptor agonist which lowers intraocular pressure by increasing uveoscleral outflow of aqueous humor.

• •Hypersensitivity to Travoprost or any component of the formulation.
• •Not recommended for use in children under 18 years of age due to lack of safety and efficacy data.

Store below 30°C. Protect from light. Do not freeze. Keep the bottle tightly closed when not in use. Discard any remaining solution 4 weeks after first opening.

Ocular overdose is unlikely to cause toxicity. Systemic overdose is also unlikely due to the low systemic absorption. If overdose occurs, treatment should be symptomatic and supportive.

Pregnancy Category C. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Travoprost is excreted in human milk, so caution should be exercised when administered to a nursing woman.